Skip to main content
Erschienen in: Zeitschrift für Gerontologie und Geriatrie 6/2021

23.09.2020 | Original Contributions

Risk of falls in patients with low bone mineral density

Analysis of placebo arms from clinical trials

verfasst von: Luis Möckel

Erschienen in: Zeitschrift für Gerontologie und Geriatrie | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Falls are a major risk factor for osteoporotic fractures. Therefore, the aim of this study was to analyze the risk of falls in patients with low bone mineral density (BMD) and osteoporosis.

Methods

The risk of falls in patients with low BMD and/or osteoporosis was analyzed using data from placebo arms of clinical trials, indexed on clinicaltrials.gov. The risk was estimated using a single arm meta-analysis method and by applying a binary random effects model. In addition, meta-regression analyses were performed to identify associations between risk of falls and age, body mass index (BMI) and BMD.

Results

A total of 8762 patients from placebo arms of clinical trials were included into the analysis. Risk of falls was 5.2% (0.052, 95% confidence interval [95% CI] 0.022–0.082; n = 8714; I2 = 97.3%, p ≤ 0.001) in patients with low BMD and/or osteoporosis and 5.9% (0.059, 95% CI 0.036–0.083; n = 7819; I2 = 87.8%, p ≤ 0.001) in patients with osteoporosis. A significant association with risk of falls was identified for age in patients with low BMD and/or osteoporosis. BMD at total hip (TH; coefficient −0.077, 95% CI: −0.113–−0.040, p ≤ 0.001; n = 7715) and femoral neck (FN; coefficient −0.044, 95% CI −0.065–−0.023, p ≤ 0.001; n = 7662) were significantly associated with risk of falls in patients with osteoporosis.

Conclusion

This analysis identified the risk of falls in patients with low BMD and osteoporosis and an association of falls with age and BMD. Therefore, patients with osteoporosis need to receive mandatory fall risk mitigation measures, and the BMD at total hip or femoral neck could function as an indicator for the risk of falling.
Literatur
1.
Zurück zum Zitat Adachi JD, Berger C, Barron R, Weycker D, Anastassiades TP et al (2019) Predictors of imminent non-vertebral fracture in elderly women with osteo-porosis, low bone mass, or a history of fracture, based on data from the population-based Canadian Multicentre Osteoporosis Study (CaMos). Arch Osteoporos 14:53PubMedCrossRef Adachi JD, Berger C, Barron R, Weycker D, Anastassiades TP et al (2019) Predictors of imminent non-vertebral fracture in elderly women with osteo-porosis, low bone mass, or a history of fracture, based on data from the population-based Canadian Multicentre Osteoporosis Study (CaMos). Arch Osteoporos 14:53PubMedCrossRef
2.
Zurück zum Zitat Bonafede M, Shi N, Barron R, Li X, Crittenden DB et al (2016) Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data. Arch Osteoporos 11:26PubMedPubMedCentralCrossRef Bonafede M, Shi N, Barron R, Li X, Crittenden DB et al (2016) Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data. Arch Osteoporos 11:26PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Chen KW, Chang SF, Lin PL (2017) Frailty as a predictor of future fracture in older adults: a systematic review and meta-analysis. Worldviews Evid Based Nurs 14:282e93 Chen KW, Chang SF, Lin PL (2017) Frailty as a predictor of future fracture in older adults: a systematic review and meta-analysis. Worldviews Evid Based Nurs 14:282e93
4.
Zurück zum Zitat Woolf AD, Akesson K (2003) Preventing fractures in elderly people. BMJ 327:89e95CrossRef Woolf AD, Akesson K (2003) Preventing fractures in elderly people. BMJ 327:89e95CrossRef
9.
Zurück zum Zitat McCloskey EV, Eastell R, McClung M, Pannacciulli N, Wand C et al (2019) A pooled analysis of fall incidence from placebo-controlled trials of Denosumab. In: Osteoporosis international 2019 Paris, France, Apr 4–7 (abstract OC29) McCloskey EV, Eastell R, McClung M, Pannacciulli N, Wand C et al (2019) A pooled analysis of fall incidence from placebo-controlled trials of Denosumab. In: Osteoporosis international 2019 Paris, France, Apr 4–7 (abstract OC29)
11.
Zurück zum Zitat Armamento-Villareal R, Aguirre L, Napoli N, Shah K, Hilton T et al (2014) Changes in thigh muscle volume predict bone mineral density response to lifestyle therapy in frail, obese older adults. Osteoporos Int 25:551–558PubMedCrossRef Armamento-Villareal R, Aguirre L, Napoli N, Shah K, Hilton T et al (2014) Changes in thigh muscle volume predict bone mineral density response to lifestyle therapy in frail, obese older adults. Osteoporos Int 25:551–558PubMedCrossRef
12.
Zurück zum Zitat De Sousa e Silva Araujo EC, Pagotto V, Aparecida Silveira E (2017) Association of bone mineral density with frailty, pre-frailty and osteoporosis in community-dwelling elderly: a prospective study. J Geriatr Med Gerontol 3:33 De Sousa e Silva Araujo EC, Pagotto V, Aparecida Silveira E (2017) Association of bone mineral density with frailty, pre-frailty and osteoporosis in community-dwelling elderly: a prospective study. J Geriatr Med Gerontol 3:33
13.
Zurück zum Zitat Mera P, Laue K, Wei J, Berger JM, Karsenty G (2016) Osteocalcin is necessary and sufficient to maintain muscle mass in older mice. Mol Metab 5:1042–1047PubMedPubMedCentralCrossRef Mera P, Laue K, Wei J, Berger JM, Karsenty G (2016) Osteocalcin is necessary and sufficient to maintain muscle mass in older mice. Mol Metab 5:1042–1047PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef
18.
Zurück zum Zitat U.S. National Library of Medicine ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 4 July 2020 (Study registry entries can be retrieved using the NCT numbers: NCT00439647, NCT00885170, NCT01575834, NCT00089791, NCT00729183, NCT01144377, NCT00112437, NCT00471237, NCT00433160, NCT02016716, NCT00896532, NCT00043186) U.S. National Library of Medicine ClinicalTrials.gov. https://​clinicaltrials.​gov. Accessed 4 July 2020 (Study registry entries can be retrieved using the NCT numbers: NCT00439647, NCT00885170, NCT01575834, NCT00089791, NCT00729183, NCT01144377, NCT00112437, NCT00471237, NCT00433160, NCT02016716, NCT00896532, NCT00043186)
21.
Zurück zum Zitat Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765PubMedCrossRef Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765PubMedCrossRef
22.
Zurück zum Zitat Brixen K, Chapurlat R, Cheung AM, Keaveny TM, Fuerst T et al (2013) Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab 98:571–580PubMedCrossRef Brixen K, Chapurlat R, Cheung AM, Keaveny TM, Fuerst T et al (2013) Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab 98:571–580PubMedCrossRef
23.
Zurück zum Zitat Recker RR, Benson CT, Matsumoto T, Bolognese MA, Robins DA et al (2015) A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res 30(2):216–224. https://doi.org/10.1002/jbmr.2351PubMedCrossRef Recker RR, Benson CT, Matsumoto T, Bolognese MA, Robins DA et al (2015) A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res 30(2):216–224. https://​doi.​org/​10.​1002/​jbmr.​2351PubMedCrossRef
25.
Zurück zum Zitat Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Papapoulos S et al (2011) The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 96(8):2441–2449PubMedCrossRef Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Papapoulos S et al (2011) The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 96(8):2441–2449PubMedCrossRef
26.
Zurück zum Zitat Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR et al (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-Month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47:493–502. https://doi.org/10.1016/j.bone.2010.05.022PubMedCrossRef Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR et al (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-Month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47:493–502. https://​doi.​org/​10.​1016/​j.​bone.​2010.​05.​022PubMedCrossRef
28.
Zurück zum Zitat McClung MR, Lewiecki M, Cohen SB, Bolognese MA, Woodson GC et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831PubMedCrossRef McClung MR, Lewiecki M, Cohen SB, Bolognese MA, Woodson GC et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831PubMedCrossRef
29.
Zurück zum Zitat Robbins AS et al (1989) Predictors of falls among elderly people. Results of two population-based studies. Arch Intern Med 149:1628–1633PubMedCrossRef Robbins AS et al (1989) Predictors of falls among elderly people. Results of two population-based studies. Arch Intern Med 149:1628–1633PubMedCrossRef
30.
Zurück zum Zitat Sheehan KJ, O’Connell MDL, Cunningham C, Crosby L, Kenn RA (2013) The relationship between increased body mass index and frailty on falls in community dwelling older adults. BMC Geriatr 13:132PubMedPubMedCentralCrossRef Sheehan KJ, O’Connell MDL, Cunningham C, Crosby L, Kenn RA (2013) The relationship between increased body mass index and frailty on falls in community dwelling older adults. BMC Geriatr 13:132PubMedPubMedCentralCrossRef
Metadaten
Titel
Risk of falls in patients with low bone mineral density
Analysis of placebo arms from clinical trials
verfasst von
Luis Möckel
Publikationsdatum
23.09.2020
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Gerontologie und Geriatrie / Ausgabe 6/2021
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI
https://doi.org/10.1007/s00391-020-01784-5

Weitere Artikel der Ausgabe 6/2021

Zeitschrift für Gerontologie und Geriatrie 6/2021 Zur Ausgabe

Mitteilungen der DGG

Mitteilungen der DGG